Contributions
Abstract: EP1375
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - MS symptoms
Background: Sustained-release fampridine (SR-fampridine), a potassium channel blocker, has been approved to improve walking in multiple sclerosis (MS) patients but also the performance of activities of daily living. Few data are available about its effects on quality of life (QoL) in MS patients.
Objective: To analyze the effect of SR-fampridine on quality of life in real-world setting in MS patients, its evolution and the influence of different clinical parameters.
Method: We performed an observational, prospective study of consecutive patients with MS that need SR-fampridine. Time 25 foot walk (T25FW) and MS walking scale-12 (MSWS-12) were done before and 14 days after the start of treatement. Quality of life of responders was evaluated by TLS-QoL10 at baseline, 1, 3 and 6 months after start of SR-fampridine. Clinical parameters like sex, age, EDSS, disease form and duration and walking time were collected and their impact on TLS-QoL10 score evolution was searched.
Result: We included 123 MS patients, 104 (84.55%) of which were responders and TLS-Qol 10 data were available in 92 responders (88.46%). In the responders group, 59.78% (55/92) of patients were women, 34.78% had a relapsing-remitting form of MS, 65.22% a progressive form (39.13% secondary and 26.08% primary). Mean EDSS of this group was 5.2 (+/-1.11) and mean disease duration was 194.84 months (+/-121.07). We observed a significant increase of QoL score over time of the study, due to an early increase as the first month of treatment (4.1 at baseline vs 5.4 at 1st month, p< 0.001), which remained at 6 months (6.2 at M3 and 6.4 at M6). This increase of TLS-QoL10 score was influenced by sex (women were more responder than men), age (increase was earlier in younger than older patients), disease form (patients with relapsing-remitting and secondary progressive form were more responder than those with primary progressive form). EDSS and improvement of walking time between baseline and J14 had no effect on TLS-QoL10 score.
Conclusion: The results of this study suggested that SR-fampridine may have an early positive effect on quality of life. These results were independent of the effect on walking scales.
Disclosure: Chevanne: nothing to disclose
Creveuil: nothing to disclose
Derache: has received funding for speakers honoraria from Merck-Serono, Biogen-Idec, Novartis, Sanofi-genzyme and Roche
Defer: receivedpersonalcompensation for scientificadvisoryboardfromBiogenIdec, Novartis, Genzymeand TevapharmaceuticalIndustries Ltd and has receivedfundingfor traveland/or speaker honorariafromMerckSerono, BiogenIdec, Novartis, Genzymeand TevapharmaceuticalIndustries Ltd.
Abstract: EP1375
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - MS symptoms
Background: Sustained-release fampridine (SR-fampridine), a potassium channel blocker, has been approved to improve walking in multiple sclerosis (MS) patients but also the performance of activities of daily living. Few data are available about its effects on quality of life (QoL) in MS patients.
Objective: To analyze the effect of SR-fampridine on quality of life in real-world setting in MS patients, its evolution and the influence of different clinical parameters.
Method: We performed an observational, prospective study of consecutive patients with MS that need SR-fampridine. Time 25 foot walk (T25FW) and MS walking scale-12 (MSWS-12) were done before and 14 days after the start of treatement. Quality of life of responders was evaluated by TLS-QoL10 at baseline, 1, 3 and 6 months after start of SR-fampridine. Clinical parameters like sex, age, EDSS, disease form and duration and walking time were collected and their impact on TLS-QoL10 score evolution was searched.
Result: We included 123 MS patients, 104 (84.55%) of which were responders and TLS-Qol 10 data were available in 92 responders (88.46%). In the responders group, 59.78% (55/92) of patients were women, 34.78% had a relapsing-remitting form of MS, 65.22% a progressive form (39.13% secondary and 26.08% primary). Mean EDSS of this group was 5.2 (+/-1.11) and mean disease duration was 194.84 months (+/-121.07). We observed a significant increase of QoL score over time of the study, due to an early increase as the first month of treatment (4.1 at baseline vs 5.4 at 1st month, p< 0.001), which remained at 6 months (6.2 at M3 and 6.4 at M6). This increase of TLS-QoL10 score was influenced by sex (women were more responder than men), age (increase was earlier in younger than older patients), disease form (patients with relapsing-remitting and secondary progressive form were more responder than those with primary progressive form). EDSS and improvement of walking time between baseline and J14 had no effect on TLS-QoL10 score.
Conclusion: The results of this study suggested that SR-fampridine may have an early positive effect on quality of life. These results were independent of the effect on walking scales.
Disclosure: Chevanne: nothing to disclose
Creveuil: nothing to disclose
Derache: has received funding for speakers honoraria from Merck-Serono, Biogen-Idec, Novartis, Sanofi-genzyme and Roche
Defer: receivedpersonalcompensation for scientificadvisoryboardfromBiogenIdec, Novartis, Genzymeand TevapharmaceuticalIndustries Ltd and has receivedfundingfor traveland/or speaker honorariafromMerckSerono, BiogenIdec, Novartis, Genzymeand TevapharmaceuticalIndustries Ltd.